Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PDSB save search
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: 12.36%
H: 8.33%
C: 6.67%
atile-002 versamune biotech hpv cancer key trial
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
Published: 2024-03-27 (Crawled : 00:00) - biospace.com/
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: -10.71%
H: 8.5%
C: -3.75%
biotech year update financial results
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
Published: 2024-03-20 (Crawled : 12:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: 0.21%
H: 6.38%
C: 2.34%
conference business year update financial results
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
Published: 2024-03-13 (Crawled : 12:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: 3.78%
H: 5.27%
C: -1.04%
infectimune patent biotech publication research preclinical grant
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
Published: 2024-01-22 (Crawled : 22:00) - globenewswire.com
BAX | $40.93 -0.22% 0.0% 3
|
Health Technology
|
| O: 0.59%
H: 0.18%
C: -1.36%
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: 1.11%
H: 10.79%
C: 10.79%
biotech medical
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
Published: 2024-01-16 (Crawled : 13:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: -5.0%
conference biotech
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-12-04 (Crawled : 22:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: -0.38%
H: 1.9%
C: -0.38%
nasdaq grant
APYX MEDICAL CORPORATION APPOINTS MATTHEW HILL AS CHIEF FINANCIAL OFFICER
Published: 2023-11-28 (Crawled : 14:00) - apyxmedical.com
FNCTF | News | $11.16 1.13% -20.84% 0
|
Communications
|
| O: -2.99%
H: 0.0%
C: 0.0%
SSKN | $0.56 3.7% 1.64% 5.6K
|
Health Technology
|
| O: -4.51%
H: 19.77%
C: 0.23%
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: -3.39%
H: 0.7%
C: -6.49%
APYX | $1.5 13.64% 11.71% 1
|
Health Technology
|
| O: 0.0%
H: 10.88%
C: 1.02%
corporation medical apyx financial
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
Published: 2023-11-28 (Crawled : 12:30) - globenewswire.com
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: -1.93%
H: 0.37%
C: -0.43%
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: -3.39%
H: 0.7%
C: -6.49%
PODD | $167.25 -0.01% -0.03% 660K
|
Health Technology
|
| O: -0.87%
H: 1.19%
C: -0.21%
biotech financial
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-14 (Crawled : 12:30) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: 6.57%
H: 15.36%
C: 11.25%
biotech business update financial results
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients
Published: 2023-11-09 (Crawled : 15:30) - biospace.com/
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: 4.94%
H: 4.7%
C: 0.41%
pds0101 biotech cancer trial therapy
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
Published: 2023-11-09 (Crawled : 13:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: 4.94%
H: 4.7%
C: 0.41%
pds0101 biotech cancer trial therapy show
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
Published: 2023-11-07 (Crawled : 13:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: 0.0%
H: 2.36%
C: 0.75%
conference financial results
PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
Published: 2023-10-23 (Crawled : 12:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: -0.73%
H: 2.45%
C: -2.45%
biotech biomarker cancer results study
PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: -0.42%
H: 2.3%
C: -2.92%
pds0301 drug antibody biotech cancer treat trial response
PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)
Published: 2023-10-03 (Crawled : 11:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: 0.0%
H: 3.19%
C: -14.47%
pds0101 keytruda biotech cancer
PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)
Published: 2023-10-02 (Crawled : 12:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: -0.2%
H: 5.75%
C: -6.75%
pds0101 biotech rapid tumor dna
PDS Biotech to Present at the LD Micro Main Event XVI
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: -0.78%
H: 5.33%
C: 2.96%
biotech
PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101
Published: 2023-09-25 (Crawled : 12:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: -1.15%
H: 0.58%
C: -0.78%
pds0101 biotech application potential
PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
Published: 2023-09-20 (Crawled : 20:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K
|
Health Technology
|
| O: 0.0%
H: 1.89%
C: 0.38%
conference biotech global
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 17M
|
TSLA | News | $162.13 12.06% 10.13% 170M
|
Consumer Durables
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.